Cambridge, Massachusetts -- Biopharmaceutical technology company SynDevRx has received $1 million in new equity venture capital funding, according to an SEC regulatory filing.
SynDevRx is developing "polymeric prodrugs which deliver MetAP2 inhibitors to diseased tissues."
The company says its first two drug candidates have been previously shown to shrink tumors.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 38 investors participated in the offering.
SynDevRx is still seeking $1.59 million in additional equity investment, according to the filing.